ClinicalTrials.gov
ClinicalTrials.gov Menu

Biomarker in Lung Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00989846
Recruitment Status : Unknown
Verified October 2009 by Heidelberg University.
Recruitment status was:  Recruiting
First Posted : October 6, 2009
Last Update Posted : October 14, 2009
Sponsor:
Information provided by:
Heidelberg University

Brief Summary:

Disease related biomarkers have been established decades ago, e.g. blood glucose for diabetes diagnosis and management. Their discovery has grown dramatically during the past decade and they have the potential to lead the physician in diagnosis -especially differential diagnosis - and therapy.

However, a specific serum-biomarker in lung diseases has not been established. Aim of the current study is to to measure lung specific proteins in the serum in patients with various lung diseases and to correlate those with disease severity, lung function and other laboratory results


Condition or disease Intervention/treatment
Lung Diseases Other: biomarker

Study Type : Observational
Estimated Enrollment : 120 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Feasibility Study on Establishing Biomarkers in Lung Diseases
Study Start Date : October 2009
Estimated Primary Completion Date : March 2010
Estimated Study Completion Date : June 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Diseases
U.S. FDA Resources

Group/Cohort Intervention/treatment
lung disease
patients with various chronic or acute lung diseases
Other: biomarker
measuring serum-biomarkers



Primary Outcome Measures :
  1. Serum biomarker expression [ Time Frame: 1 month ]

Biospecimen Retention:   Samples Without DNA
Serum (blood)


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with acute or chronic lung diseases
Criteria

Inclusion Criteria:

  • age >= 18
  • acute or chronic lung disease

Exclusion Criteria:

  • HIV
  • lactation or gestation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00989846


Contacts
Contact: Michael Kreuter, MD 49 / 6221 / 396 ext 1201 michael.kreuter@thoraxklinik-heidelberg.de

Locations
Germany
Thoraxklinik Heidelberg, Dept. of Pneumology and Respiratory Critical care Recruiting
Heidelberg, Germany, 69126
Contact: Michael Kreuter, MD    49 / 6221 / 396 ext 1201    michael.kreuter@thoraxklinik-heidelberg.de   
Principal Investigator: Michael Kreuter, MD         
Sponsors and Collaborators
Heidelberg University
Investigators
Principal Investigator: Michael Kreuter, MD Thoraxklinik Heidelberg, Germany
Study Director: Felix JF Herth, MD Thoraxklinik Heidelberg Germany

Publications:
Responsible Party: Dr. Michael Kreuter, Thoraxklinik Heidelberg
ClinicalTrials.gov Identifier: NCT00989846     History of Changes
Other Study ID Numbers: MK02
First Posted: October 6, 2009    Key Record Dates
Last Update Posted: October 14, 2009
Last Verified: October 2009

Keywords provided by Heidelberg University:
biomarker
lung disease

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases